Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Public ClinicalTrials.gov record NCT01284387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, 24-Month, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 Adjuvant in Subjects With Mild to Moderate Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase II clinical research study to evaluate the efficacy and safety of two different dose levels of an injectable investigational treatment (ACC-001) in subjects with Mild-to-Moderate Alzheimer's disease. ACC-001 (vanutide cridificar) is a beta amyloid fragment attached to a carrier protein. It is intended to help induce an antibody response against beta amyloid and is administered as an intramuscular injection.
Study identification
- NCT ID
- NCT01284387
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 89 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Dec 31, 2013
- Completion
- Jan 31, 2014
- Last update posted
- Jan 4, 2015
2011 – 2014
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Janssen AI Investigational Site | Sun City | Arizona | 33613 | — |
| Janssen AI Investigational Site | La Jolla | California | 92093 | — |
| Janssen AI Investigational Site | Long Beach | California | 90806 | — |
| Janssen AI Investigational Site | Los Angeles | California | 90095 | — |
| Janssen AI Investigational Site | Oxnard | California | 93030 | — |
| Janssen AI Investigational Site | San Diego | California | 92103 | — |
| Janssen AI Investigational Site | San Francisco | California | 94143 | — |
| Janssen AI Investigational Site | Washington D.C. | District of Columbia | 20057 | — |
| Janssen AI Investigational Site | Miami | Florida | 33137 | — |
| Janssen AI Investigational Site | Miami | Florida | 33410 | — |
| Janssen AI Investigational Site | Ocala | Florida | 34471 | — |
| Janssen AI Investigational Site | Orlando | Florida | 32806 | — |
| Janssen AI Investigational Site | Sunrise | Florida | 33351 | — |
| Janssen AI Investigational Site | Tampa | Florida | 33609 | — |
| Janssen AI Investigational Site | Tampa | Florida | 33617 | — |
| Janssen AI Investigational Site | West Palm Beach | Florida | 33407 | — |
| Janssen AI Investigational Site | Scarborough | Maine | 04074 | — |
| Janssen AI Investigational Site | Boston | Massachusetts | 02115 | — |
| Janssen AI Investigational Site | Kansas City | Missouri | 64111 | — |
| Janssen AI Investigational Site | Las Vegas | Nevada | 89106 | — |
| Janssen AI Investigational Site | Princeton | New Jersey | 08540 | — |
| Janssen AI Investigational Site | Albany | New York | 12205 | — |
| Janssen AI Investigational Site | New York | New York | 10032 | — |
| Janssen AI Investigational Site | Centerville | Ohio | 45459 | — |
| Janssen AI Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01284387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2015 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01284387 live on ClinicalTrials.gov.